Concepedia

Intravenous fosaprepitant for the prevention of chemotherapy‐induced vomiting in children: A double‐blind, placebo‐controlled, phase III randomized trial

Venkatraman Radhakrishnan, Archit Joshi, Jaikumar Govindaswamy Ramamoorthy, Rajaraman Swaminathan, Prasanth Ganesan, Trivadi S. Ganesan, Manikandan Dhanushkodi, Tenali Gnana Sagar

Pediatric Blood & Cancer · 2018 · 37 citations · 12 references

DOI

Abstract

Addition of fosaprepitant to ondansetron and dexamethasone improved chemotherapy-induced vomiting control in children treated with moderately or highly emetogenic chemotherapy.

References

12

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1.6K citations · Full text

, , +15

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

L. Lee Dupuis, Sabrina Boodhan, Mark T. Holdsworth et al. · Pediatric Blood & Cancer · 2013 · 147 citations

Acute and delayed nausea and emesis control in pediatric oncology patients

Mark T. Holdsworth, Dennis W. Raisch, Jami D. Frost · Cancer · 2006 · 112 citations · Full text

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

Hyoung Jin Kang, Susan Loftus, Arlene Taylor et al. · The Lancet Oncology · 2015 · 95 citations

, , +5

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

Cindy Weinstein, Karin Jordan, S.A. Green et al. · Annals of Oncology · 2015 · 80 citations · Full text